Pharma: Page 7
-
Permission granted by City of Hope
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Christopher Furlong via Getty Images
What’s in a drug name? More than you might think.
From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.
By Alexandra Pecci • June 4, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Courtesy of Merck & Co.
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024 -
Justin Sullivan via Getty Images
After two Big Pharma deals, Nimbus looks to keep the hits coming
With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.
By Kelly Bilodeau • June 3, 2024 -
Stock via Getty Images
Q&AIn an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
By Amy Baxter • June 3, 2024 -
Permission granted by Cravath, Swaine & Moore
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
To lower drug prices, lawmakers are turning to the drug patent system to outlaw some common practices — but a former patent agency director says it’s the wrong way to go.
By Michael Gibney • May 30, 2024 -
stock via Getty Images
FTC request may signal trouble for Novo/Catalent deal
As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.
By Kelly Bilodeau • May 29, 2024 -
Stock via Getty Images
As weight loss booms, drugmakers look for an edge with oral options
Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.
By Amy Baxter • May 28, 2024 -
Stock via Getty Images
Where competition is heating up in pharma
The stage is set for potential blockbuster-level showdowns targeting these three indications.
By Meagan Parrish • May 24, 2024 -
Dan Kitwood/Getty Images via Getty Images
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.
By Michael Gibney • May 23, 2024 -
Mario Tama via Getty Images
Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?
Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.
By Amy Baxter • May 22, 2024 -
Getty Images via Getty Images
Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field
Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.
By Michael Gibney • May 22, 2024 -
Stock via Getty Images
After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era
Heather Dean discusses the company’s neuroscience pipeline in epilepsy and narcolepsy and moving from a mass market to a rare disease mentality.
By Alexandra Pecci • May 21, 2024 -
Stock via Getty Images
3 up-and-coming US biotech hotspots
These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.
By Alexandra Pecci • May 21, 2024 -
Leon Neal / Getty Images via Getty Images
Why AlphaFold 3 is stirring up so much buzz in pharma
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
By Kelly Bilodeau • May 20, 2024 -
Stock via Getty Images
Why H5N1 has scientists and regulators on edge
While the H5N1 threat to humans is still low, the recent influenza outbreak in cattle is presenting strange and challenging hurdles for containment.
By Meagan Parrish • May 17, 2024 -
Permission granted by Novartis
Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large
Execs from J&J, Novartis, Novo Nordisk and AbbVie sound off on the Inflation Reduction Act, supply issues and launch preparations in a tricky environment.
By Michael Gibney • May 16, 2024 -
Spencer Platt via Getty Images
As Lilly surges, headwinds against its weight loss drugs are growing
After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.
By Amy Baxter • May 15, 2024 -
Courtesy of Eli Lilly
Big Pharma’s most improved drugs: a new generation of blockbusters
The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.
By Michael Gibney • May 14, 2024 -
Courtesy of AbbVie
Biosimilars are gaining ground. The IRA could push them even further next year.
As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.
By Amy Baxter • May 13, 2024 -
Stock via Getty Images
5 trends impacting drug spend in the U.S.
Key factors changing how much Americans spend on prescriptions.
By Kelly Bilodeau • May 13, 2024 -
Permission granted by Daiichi Sankyo
Q&AThe Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
By Meagan Parrish • May 10, 2024 -
jetcityimage via Getty Images
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.
By Michael Gibney • May 9, 2024 -
Jemal Countess via Getty Images
OpinionThe judicial microscope on abortion meds puts FDA and industry in a precarious spot
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat.
By Meg Alexander • May 9, 2024 -
Permission granted by AstraZeneca
Q&AAZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024
Previous
